Simplicity Solutions’s Jazz Pharmaceuticals JAZZ Stock Holding History

Simplicity Solutions’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,546	Closed	-$260K	–	708
2018 Q3	$260K	Sell	1,546 -23	-1%	-$3.96K	0.01%	434
2018 Q2	$270K	Buy	+1,569	New	+$256K	0.02%	390
2016 Q1	–	Sell	-14,127	Closed	-$1.99M	–	352
2015 Q4	$1.99M	Buy	+14,127	New	+$1.96M	0.23%	117

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Simplicity Solutions's JAZZ Position: Q4 2018 in Review

Simplicity Solutions sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 1,546 shares — an estimated $260K sold.

Simplicity Solutions first reported a position in JAZZ in Q4 2015 and held it in 3 quarters. The position peaked at $1.99M in Q4 2015. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

Simplicity Solutions reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Simplicity Solutions sold 1,546 Jazz Pharmaceuticals shares in Q4 2018, an estimated $260K.
Simplicity Solutions first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 3 quarters.
Simplicity Solutions's Jazz Pharmaceuticals position peaked at $1.99M in Q4 2015.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Simplicity Solutions's 13F filing for Q4 2018, filed 13 Feb 2019.